Temasek Holdings Private Ltd Lowers Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Temasek Holdings Private Ltd reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,355,832 shares of the company's stock after selling 350,513 shares during the period. Temasek Holdings Private Ltd owned 3.72% of Denali Therapeutics worth $156,015,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Denali Therapeutics by 879.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after purchasing an additional 1,847 shares in the last quarter. CWM LLC grew its holdings in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC purchased a new stake in shares of Denali Therapeutics in the third quarter valued at $73,000. Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after purchasing an additional 580 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after purchasing an additional 920 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI traded up $1.64 during trading on Friday, hitting $24.96. 186,370 shares of the stock were exchanged, compared to its average volume of 1,057,754. The company's fifty day simple moving average is $26.85 and its 200-day simple moving average is $24.58. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of -8.99 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the company posted ($0.72) earnings per share. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now directly owns 29,096 shares in the company, valued at $844,656.88. The trade was a 50.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander O. Schuth sold 15,558 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. The trade was a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,578 shares of company stock worth $2,474,440. Corporate insiders own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Jefferies Financial Group boosted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Bank of America boosted their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 price target on shares of Denali Therapeutics in a research report on Thursday, November 7th. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Finally, Cantor Fitzgerald cut Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, October 7th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, Denali Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $38.90.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.